von Scholten Bernt Johan, Reinhard Henrik, Hansen Tine Willum, Lindhardt Morten, Petersen Claus Leth, Wiinberg Niels, Hansen Peter Riis, Parving Hans-Henrik, Jacobsen Peter Karl, Rossing Peter
Steno Diabetes Center, Niels Steensens Vej 1, Gentofte, 2820, Denmark.
Center for Functional and Diagnostic Imaging and Research, Hvidovre Hospital, University of Copenhagen, Compenhagen, Denmark.
Cardiovasc Diabetol. 2015 May 21;14:59. doi: 10.1186/s12933-015-0225-0.
In patients with type 2 diabetes, cardiovascular disease (CVD) is the major cause of morbidity and mortality. We evaluated the combination of NT-proBNP and coronary artery calcium score (CAC) for prediction of combined fatal and non-fatal CVD and mortality in patients with type 2 diabetes and microalbuminuria (>30 mg/24-h), but without known coronary artery disease. Moreover, we assessed the predictive value of a predefined categorisation of patients into a high- and low-risk group at baseline.
Prospective study including 200 patients. All received intensive multifactorial treatment. Patients with baseline NT-proBNP > 45.2 ng/L and/or CAC ≥ 400 were stratified as high-risk patients (n = 133). Occurrence of fatal- and nonfatal CVD (n = 40) and mortality (n = 26), was traced after 6.1 years (median).
High-risk patients had a higher risk of the composite CVD endpoint (adjusted hazard ratio [HR] 10.6 (95 % confidence interval [CI] 2.4-46.3); p = 0.002) and mortality (adjusted HR 5.3 (95 % CI 1.2-24.0); p = 0.032) compared to low-risk patients. In adjusted continuous analysis, both higher NT-proBNP and CAC were strong predictors of the composite CVD endpoint and mortality (p ≤ 0.0001). In fully adjusted models mutually including NT-proBNP and CAC, both risk factors remained associated with risk of CVD and mortality (p ≤ 0.022). There was no interaction between NT-proBNP and CAC for the examined endpoints (p ≥ 0.31).
In patients with type 2 diabetes and microalbuminuria but without known coronary artery disease, NT-proBNP and CAC were strongly associated with fatal and nonfatal CVD, as well as with mortality. Their additive prognostic capability holds promise for identification of patients at high risk.
在2型糖尿病患者中,心血管疾病(CVD)是发病和死亡的主要原因。我们评估了N末端B型利钠肽原(NT-proBNP)和冠状动脉钙化评分(CAC)相结合,对2型糖尿病合并微量白蛋白尿(>30mg/24小时)但无已知冠状动脉疾病患者的致命和非致命性CVD及死亡率的预测价值。此外,我们评估了在基线时将患者预先分类为高危和低危组的预测价值。
前瞻性研究纳入200例患者。所有患者均接受强化多因素治疗。基线NT-proBNP>45.2ng/L和/或CAC≥400的患者被分层为高危患者(n = 133)。在6.1年(中位数)后追踪致命和非致命性CVD(n = 40)及死亡率(n = 26)的发生情况。
与低危患者相比,高危患者发生复合CVD终点事件的风险更高(调整后风险比[HR] 10.6(95%置信区间[CI] 2.4 - 46.3);p = 0.002),死亡率更高(调整后HR 5.3(95%CI 1.2 - 24.0);p = 0.032)。在调整后的连续分析中,较高的NT-proBNP和CAC均是复合CVD终点事件和死亡率的强预测因素(p≤0.0001)。在同时纳入NT-proBNP和CAC的完全调整模型中,两个危险因素均与CVD风险和死亡率相关(p≤0.022)。对于所检查的终点事件,NT-proBNP和CAC之间没有交互作用(p≥0.31)。
在2型糖尿病合并微量白蛋白尿但无已知冠状动脉疾病的患者中,NT-proBNP和CAC与致命和非致命性CVD以及死亡率密切相关。它们的相加预后能力有望用于识别高危患者。